New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:17 EDTCYCCCyclacel receives U.S., EU patents for sapacitabine used with HDAC inhibitors
Cyclacel Pharmaceuticals announced the issuance of U.S. Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with histone deacetylase, or HDAC, inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively.
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
09:15 EDTCYCCOn The Fly: Pre-market Movers
HIGHER: Anavex Life Sciences (AVXL), up 20.5% after 3-71 data published in Neurodegenerative Diseases... Oramed Pharmaceuticals (ORMP), up 16.7% after signing up to $50M licensing and investment agreements for insulin in China... Horizon Pharma (HZNP), up 3.8% after receiving EC approval for Ravicti... Fitbit (FIT), up 4.2% after being upgraded to Overweight from Equal Weight at Barclays... Sarepta Therapeutics (SRPT), up 1.6% following a positive mention by Barron's. LOWER: Cyclacel Pharmaceuticals (CYCC) and AEterna Zentaris (AEZS), down 24.5% and 13.6%, respectively, following a Tweet by KaloBios (KBIO) CEO Martin Shkreli... Supercom (SPBC), down 21.6% after reporting preliminary third quarter revenue... Macrocure (MCUR), down 11.5% after announcing that the company's CFO and Chief Medical Officer are stepping down... lululemon (LULU), down 4.4% after being downgraded to Underperform from Market Perform at FBR Capital... Office Depot (ODP), down 2.8% after the NY Post reported that regulators are preparing to block Staples' (SPLS) proposed acquisition of Office Depot... SouFun (SFUN), down 2% after being downgraded to Neutral from Buy at Goldman.
08:59 EDTCYCCCyclacel Pharmaceuticals, Aeterna Zentaris 'worthless,' says Shkreli
Martin Shkreli, the CEO KaloBios (KBIO) and Turing Pharma, said in a tweet that Cyclacel Pharmaceuticals (CYCC) and Aeterna Zentaris (AEZS) shares are "worthless." Shares of both stocks are indicated lower this morning following Shkreli's Twitter post. Reference Link
November 23, 2015
07:17 EDTCYCCCyclacel Pharmaceuticals says CDK2/9 inhibitor prolings survival
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use